[ad_1]
She said: We will be submitting a license application “very soon”
The CEO of Pfizer, Albert Burla, announced yesterday, Tuesday, that the American pharmaceutical group will file “very soon” a license application to market its anti-Corona vaccine in the United States, which will, if all goes well, the start of vaccination in December.
“We are about to submit an emergency license application,” Burla said at a conference hosted by the Statenews website.
The chief executive of Pfizer has not confirmed or denied whether the application will be submitted this week, adding that he previously said the application would likely be submitted in the third week of November, according to the “French”.
This experimental vaccine was developed by Pfizer in cooperation with the German company Biontech.
The Emergency License is a temporary or conditional license granted by the United States Drugs Agency, “the FDA”, to deal with an emergency such as the Corona pandemic.
The agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine subsequently emerge.
The United States Food and Drug Administration did not specify how long it would take to review the vaccine’s efficacy and safety data, which are the two main criteria for it to obtain an emergency license, in addition to its ability to produce large doses.
The Pfizer vaccine is one of three experimental vaccines on which the European Medicines Agency continues to conduct fast-track clinical trials.
The other two vaccines have evolved: Oxford AstraZeneca and Moderna.
The American company Pfizer, the new Corona virus
Pfizer Announces Corona Vaccination Begins On This Date
Sabaq electronic journal
Previously
11/18/2020
The CEO of Pfizer, Albert Burla, announced yesterday, Tuesday, that the American pharmaceutical group will file “very soon” an application for a license to market its anti-Corona vaccine in the United States, which will allow, if all goes well, the start of vaccination next December.
“We are about to submit an emergency license application,” Burla said at a conference hosted by the Statenews website.
The chief executive of Pfizer has not confirmed or denied whether the request will be submitted this week, noting that he previously said the request would likely be submitted in the third week of November, according to “French”.
This experimental vaccine was developed by Pfizer in cooperation with the German company Biontech.
The Emergency License is a temporary or conditional license granted by the United States Drugs Agency, “the FDA”, to deal with an emergency such as the Corona pandemic.
The agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine subsequently emerge.
The United States Food and Drug Administration did not mention how long it would take to review the vaccine’s efficacy and safety data, which are the two main criteria for it to obtain an emergency license. , in addition to the ability to produce large doses.
The Pfizer vaccine is one of three experimental vaccines on which the European Medicines Agency continues to conduct fast-track clinical trials.
The other two vaccines have evolved, Oxford AstraZeneca and Moderna.
November 18, 2020 – Rabi` Al-Thani 3 1442
10h26
She said: We will be submitting a license application “very soon”
The CEO of Pfizer, Albert Burla, announced yesterday, Tuesday, that the American pharmaceutical group will file “very soon” a license application to market its anti-Corona vaccine in the United States, which will, if all goes well, the start of vaccination in December.
“We are about to submit an emergency license application,” Burla said at a conference hosted by the Statenews website.
The chief executive of Pfizer has not confirmed or denied whether the candidacy will be submitted this week, adding that he previously said the candidacy would likely be filed in the third week of November, according to the “French”.
This experimental vaccine was developed by Pfizer in cooperation with the German company Biontech.
The Emergency License is a temporary or conditional license granted by the United States Drugs Agency, “the FDA”, to deal with an emergency such as the Corona pandemic.
The agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine subsequently emerge.
The United States Food and Drug Administration did not specify how long it would take to review the vaccine’s efficacy and safety data, which are the two main criteria for it to obtain an emergency license, in addition to its ability to produce large doses.
The Pfizer vaccine is one of three experimental vaccines on which the European Medicines Agency continues to conduct fast-track clinical trials.
The other two vaccines have evolved: Oxford AstraZeneca and Moderna.
[ad_2]
Source link
